ETC-216 - Phospholipid Therapy for Coronary Heart Disease (CHD) Patients
Key Data:
Drug (Brand/Generic)
ETC-216
Company/Licensee
Esperion Therapeutics / Pfizer
Therapy Class
Phospholipid
Product Description
Synthetic variant of HDL
Current Indication
Treatment of atherosclerosis
Market Sector
CVD
Development Status
Phase II
